Simulations Plus Inc (SLP)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Simulations Plus Reports Third Quarter Fiscal 2026 Financial Results

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development...

Form PREM14A - Preliminary proxy statements relating to merger or acquisition

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Simulations Plus Advances Agentic Drug Development with NVIDIA BioNeMo Agent Toolkit

New capabilities connect AI agents, scientific literature, and validated computational engines to accelerate model-informed drug development...

Simulations Plus, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – SLP

The DJS Law Group announces that it is investigating claims on behalf of investors of Simulations Plus, Inc. (“Simulations Plus” or “the Company”...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Simulations Plus to Be Acquired by Altaris For Approximately $375 Million

Stockholders to Receive $18.50 Per Share in Cash Representing a 26% Premium to 60-day Volume-Weighted Average Price Transaction to Strengthen...